COMPANY

Allterum Therapeutics

Keywords: oncology antibody monoclonal antibody cancer Lymphoblastic Lymphoma Acute Lymphoblastic Leukemia ALL 4A10

Location: Houston, TX · source · Oct 14, 2026

Profile checked Oct 10, 2026

Timeline

Jun 1, 2026 Trial start Phase 1: First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves i source ↗

2028-05 (ESTIMATED) · Phase 1 · First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Bod · NCT07586618

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT07586618	First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.	Phase 1	Recruiting	Jun 1, 2026	2028-05 (estimated)